CansinoBio (06185) opened 15% higher in Hong Kong trading, with shares last up 15% at HK$26.84, recording a turnover of HK$3.88 million. The surge comes after Moderna and Merck announced on the evening of August 19 that their personalized mRNA cancer vaccine achieved success in a large-scale Phase 3 clinical trial, sending Moderna's stock soaring over 170% at the close that day.

This study marks the first Phase 3 clinical trial of an mRNA tumor vaccine globally. If the vaccine receives regulatory approval for market launch, it would signify the expansion of mRNA applications from infectious disease vaccines into the oncology treatment arena, providing significant encouragement and momentum for the mRNA tumor vaccine industry.

Public information indicates that CansinoBio possesses a next-generation ISL-3C-LNP delivery system with fully proprietary intellectual property rights, which bypasses traditional overseas LNP patent barriers and is specifically designed to address the cellular immune activation requirements of therapeutic cancer vaccines. The company has multiple mRNA tumor vaccine pipelines currently in advanced development stages.

Overseas clinical data have confirmed the viability of the mRNA tumor vaccine approach, further highlighting the value of the company's delivery technology platform and opening up room for valuation recovery in its tumor vaccine pipeline.